CARAGLIA, MICHELE
 Distribuzione geografica
Continente #
EU - Europa 464
NA - Nord America 389
AS - Asia 96
AF - Africa 3
OC - Oceania 1
Totale 953
Nazione #
US - Stati Uniti d'America 388
GB - Regno Unito 209
IE - Irlanda 88
CN - Cina 48
IT - Italia 31
UA - Ucraina 30
RU - Federazione Russa 28
SE - Svezia 28
VN - Vietnam 18
FR - Francia 14
SG - Singapore 13
FI - Finlandia 11
DE - Germania 9
TR - Turchia 8
IN - India 6
ES - Italia 5
BE - Belgio 3
CI - Costa d'Avorio 3
AT - Austria 2
AL - Albania 1
AU - Australia 1
BD - Bangladesh 1
BY - Bielorussia 1
CA - Canada 1
CZ - Repubblica Ceca 1
IR - Iran 1
LT - Lituania 1
NO - Norvegia 1
PK - Pakistan 1
PL - Polonia 1
Totale 953
Città #
Southend 199
Dublin 85
Fairfield 56
Chandler 32
Ashburn 31
Menlo Park 31
Woodbridge 26
Jacksonville 24
Seattle 21
Wilmington 20
Cambridge 19
Dong Ket 18
Beijing 17
Siena 16
Ann Arbor 15
Dearborn 14
Houston 14
New York 12
Singapore 12
Princeton 10
Helsinki 9
Izmir 8
Florence 5
Málaga 5
Nanjing 5
Boardman 4
Fremont 4
Munich 4
Phoenix 4
San Diego 4
San Mateo 4
Shanghai 4
Abidjan 3
Brussels 3
Hebei 3
Moscow 3
Shenyang 3
Fuzhou 2
Hounslow 2
Jinan 2
Los Angeles 2
Nanchang 2
Santa Clara 2
Sezze 2
Tianjin 2
Vienna 2
Bangalore 1
Borghetto Lodigiano 1
Campi Bisenzio 1
Canberra 1
Dallas 1
Dhaka 1
Edinburgh 1
Espoo 1
Falkenstein 1
Giussano 1
Hangzhou 1
Islamabad 1
Jiaxing 1
Kilburn 1
Kunming 1
Kyiv 1
London 1
Minsk 1
Oslo 1
Philadelphia 1
Prague 1
Saint Louis 1
Saint Petersburg 1
Sandston 1
Taizhou 1
Tirana 1
Toronto 1
Warsaw 1
Zanjan 1
Totale 794
Nome #
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 249
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 242
Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab 182
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). 155
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients 110
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 36
Totale 974
Categoria #
all - tutte 2.811
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.811


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020130 0 0 0 0 14 23 24 20 14 21 7 7
2020/2021163 10 11 5 21 7 20 2 20 18 15 8 26
2021/202296 5 16 4 4 9 0 7 4 9 12 7 19
2022/2023110 5 12 18 15 11 17 4 7 6 7 5 3
2023/2024140 1 1 14 7 3 38 63 0 2 5 0 6
2024/202560 7 14 25 11 3 0 0 0 0 0 0 0
Totale 974